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LETTER FROM THE EDITOR
A New Beginning
I would like to take this opportunity as Editor in Chief of
BBMT to welcome our new publisher, Elsevier, and to reﬂect on
the hopes that we have for the journal’s future. BBMT has
continued to grow steadily in volume and stature over the last 2
years, and we are conﬁdent that Elsevier’s marketing strategy
will help us to expand our readership in both the domestic and
international arenas.
As is ﬁtting for this new beginning, you will notice that
BBMT now has a distinct new cover. There are some other
important changes as well that should be of interest to all
potential authors. There will no longer be any page charges to
authors for the publication of their manuscripts, and color page
charges have been signiﬁcantly reduced. In addition, BBMT will
have a new website—www.bbmt.org—where individual sub-
scribers will have full access to the journal and any supplemen-
tary material. The journal will also be a part of Science Direct,
the largest electronic platform for institutional access. I hope
that you will be pleased with these new developments.
I also want to make everyone aware of BBMT’s continuing
efforts to enhance participation of individuals who are currently
in training level positions in the ﬁeld (ie, pre- and postdoctoral
trainees, residents, interns, or anyone still below Assistant Pro-
fessor level). At the end of every year, the Associate Editors of
the journal select the recipients of the Ernest McCulloch &
James Till Award and the George Santos Award for the best
articles in Basic and Clinical Research, respectively, that are
published in BBMT with a trainee as ﬁrst author. These awards
are $5000 each and are supported by educational grants gener-
ously provided by StemSoft Software, Inc, and StemCell Ther-
apeutics, Inc. In addition, BBMT offers an honorarium of $1000
to any trainee who is ﬁrst author on a review article that is
published in the journal.
Our immediate goals for BBMT are to continue to publish
high-caliber manuscripts in both basic and clinical research
related to the ﬁeld of hematopoietic stem cell transplantation.
We are also very proud of being the unique forum for publica-
tion of an extensive series of Evidence-Based Reviews, the latest
of which is on multiple myeloma and appears in this issue. We
intend to continue to expand the volume of manuscripts per
issue over the next few years, but that of course will depend on
your participation. I encourage all members of the ASBMT, and
of the ﬁeld at-large, to select BBMT as your ﬁrst choice for
submission of manuscripts, to maximize their inﬂuence on the
ﬁeld and to directly reach those investigators who can best
appreciate their scientiﬁc contribution. Together, we can make
BBMT the premier journal in the ﬁeld, and I am sure it will serve
as a source of pride for all members of the Society.
Robert Korngold, PhD
Editor in Chief
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